ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Consistent multi-time-point brain atrophy estimation from the boundary shift integral

Leung, Kelvin K.*; Ridgway, Gerard R.; Ourselin, Sebastien; Fox, Nick C.
NeuroImage2012-2-15DOI: 10.1016/j.neuroimage.2011.10.068
54被引2阅读
引用收藏
分享

摘要

Brain atrophy measurement is increasingly important in studies of neurodegenerative diseases such as Alzheimer's disease (AD), with particular relevance to trials of potential disease-modifying drugs. Automated registration-based methods such as the boundary shift integral (BSI) have been developed to provide more precise measures of change from a pair of serial MR scans. However, when a method treats one image of the pair (typically the baseline) as the reference to which the other is compared, this systematic asymmetry risks introducing bias into the measurement. Recent concern about potential biases in longitudinal studies has led to several suggestions to use symmetric image registration, though some of these methods are limited to two time-points per subject. Therapeutic trials and natural history studies increasingly involve several serial scans, it would therefore be useful to have a method that can consistently estimate brain atrophy over multiple time-points. Here, we use the log-Euclidean concept of a within-subject average to develop affine registration and differential bias correction methods suitable for any number of time-points, yielding a longitudinally consistent multi-time-point BSI technique. Baseline, 12-month and 24-month MR scans of healthy controls, subjects with mild cognitive impairment and AD patients from the Alzheimer's Disease Neuroimaging Initiative are used for testing the bias in processing scans with different amounts of atrophy. Four tests are used to assess bias in brain volume loss from BSI: (a) inverse consistency with respect to ordering of pairs of scans 12 months apart; (b) transitivity consistency over three time-points; (c) randomly ordered back-to-back scans, expected to show no consistent change over subjects; and (d) linear regression of the atrophy rates calculated from the baseline and 12-month scans and the baseline and 24-month scans, where any additive bias should be indicated by a non-zero intercept. Results indicate that the traditional BSI processing pipeline does not exhibit significant bias due to its use of windowed sinc interpolation, but with linear interpolation and asymmetric registration, bias can be pronounced. Either improved interpolation or symmetric registration alone can greatly reduce this bias, and our proposed method combining both aspects shows no significant bias in any of the four experiments.

学科与关键词

关键词
Boundary shift integralSymmetric registrationDifferential bias correctionBrain atrophyAlzheimer's disease
相关
加载中…
  • Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection
    Leung, Kelvin K.*; Clarkson, Matthew J.; Bartlett, Jonathan W.; Clegg, Shona; Jack, Clifford R., Jr.; Weiner, Michael W.; Fox, Nick C.; Ourselin, SebastienNeuroImage, 2010, 50(2): 516-523.被引 114
  • Brain atrophy progression measured from registered serial MRI: Validation and application to Alzheimer's disease
    Fox, NC; Freeborough, PAJournal of Magnetic Resonance Imaging, 1997, 7(6): 1069-1075.被引 274
  • Cerebral atrophy measurements using Jacobian integration: Comparison with the boundary shift integral
    Boyes, Richard G.*; Rueckert, Daniel; Aljabar, Paul; Whitwell, Jennifer; Schott, Jonathan M.; Hill, Derek L. G.; Fox, Nicholas C.NeuroImage, 2006, 32(1): 159-169.被引 47
查看全部 →

发表信息

论文状态
公开发表
期刊
NeuroImage
发表日期
2012-02-15
卷期
第 59 卷, 第 4 期
页码
3995-4005
DOI
10.1016/j.neuroimage.2011.10.068
语言
ENGLISH
成果收录
SCIE
资助标注
Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Abbott; AstraZeneca AB; Bayer Schering Pharma AG; Bristol-Myers Squibb; Eisai Global Clinical Development; Elan Corporation; Genentech; GE Healthcare; GlaxoSmithKline; Innogenetics; Johnson and Johnson; Eli Lilly and Co.; Medpace, Inc.; Merck and Co., Inc.; Novartis AG; Pfizer Inc; F. Hoffman-La Roche; Schering-Plough; Synarc, Inc.; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; NIH [P30 AG010129, K01 AG030514]; Dana Foundation; Department of Health's National Institute of Health Research Centres; Medical Research Council; Alzheimer's Research UK; MRC [G0801306, G0601846] Funding Source: UKRI

作者

  • L

    Leung, Kelvin K. (通讯) (第一作者)

  • R

    Ridgway, Gerard R.

查看全部 4 位作者收起作者
  • O

    Ourselin, Sebastien

  • F

    Fox, Nick C.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417